本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 康泰医学系统(秦皇岛)股份有限公司（以下简称"公司"）2024 年年度报告 全文及其摘要已于 2025 年 4 月 29 日刊登于创业板信息披露媒体（巨潮资讯网 www.cninfo.com.cn）。为使投资者进一步了解公司的财务状况、经营情况及公司 发展规划，公司将于 2025 年 5 月 16 日(星期五)15:30-16:30 在全景网举行 2024 年度业绩说明会。本次说明会将采用网络远程方式举行，投资者可登陆全景网 "投资者关系互动平台"（h ttp :// ir .p 5w.n et）参与本次业绩说明会。 证券代码：300869 证券简称：康泰医学 公告编号：2025-038 债券代码：123151 债券简称：康医转债 康泰医学系统（秦皇岛）股份有限公司 关于举行 2024 年度业绩说明会的公告 特此公告。 康泰医学系统(秦皇岛)股份有限公司董事会 2025 年 5 月 13 日 出席本次业绩说明会的人员有：董事长胡坤先生，董事、总经理杨志山先 生，董事、董事会秘书、财务总监郑敏女士，独立董事李华女士 ...

Core Viewpoint - The company, Kangtai Medical, has reported a significant decline in performance, transitioning from profit to a net loss of 77.9026 million yuan in 2024, primarily due to weakened downstream market demand and intense competition [1][2]. Financial Performance - In 2024, Kangtai Medical achieved an operating revenue of 480 million yuan, representing a year-on-year decrease of 35.76% [2]. - The company has experienced a continuous decline in net profit for four consecutive years since 2021 [1]. Shareholder Actions - The actual controller of Kangtai Medical, Hu Kun, announced a plan to reduce his shareholding by up to 12 million shares, which is approximately 2.9865% of the total share capital, due to personal financial needs [1][2]. Business Operations - Kangtai Medical specializes in the research, production, and sales of medical diagnostic and monitoring equipment, with a product range that includes blood oxygen, electrocardiogram, ultrasound, monitoring, blood pressure, and analytical testing devices [2]. - The company has developed three main product systems: hospital-based, home-based, and others, serving various healthcare settings [2]. Challenges Faced - The company cited several challenges impacting its business, including increased competition in the global medical device market, stricter regulatory requirements, and reduced procurement budgets from governments and medical institutions [2][3]. - The decline in sales volume and prices of major products has led to a significant drop in main business income [3]. Inventory and R&D Expenses - Kangtai Medical reported a high balance of raw materials and semi-finished goods due to previous market conditions, leading to a slowdown in inventory turnover and a need to recognize a substantial inventory impairment provision of 109 million yuan [3]. - The company maintained a high level of R&D investment, with expenses amounting to 105 million yuan in 2024, which has also impacted net profit in the short term [3].

截至2025年一季报，共有3家机构持仓康泰医学，其中基金2家、其他1家，合计持股数334.63万股，持 股市值0.46亿元。 康泰医学系统(秦皇岛)股份有限公司的主营业务是医疗诊断、监护设备的研发、生产和销售。产品涵盖 血氧类、心电类、超声类、监护类、血压类等多个大类,建立了完善的研发、生产和销售体系。2023年4 月，公司Remoltar远程专业彩色多普勒超声诊断系统荣获德国IF设计奖和意大利A设计奖。2023年10 月，公司的儿童红外体温计产品斩获2023年广交会设计创新奖银奖，呼吸训练器、动态心电监护仪两款 产品斩获铜奖。 5月12日，康泰医学今日收盘13.87元，上涨2.14%，最新市净率3.02，总市值55.73亿元。 最新一期业绩显示，2025年一季报，公司实现营业收入1.12亿元，同比12.77%；净利润1643.58万元， 同比277.67%，销售毛利率58.15%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)9康泰医学-84.67-71.543.0255.73亿行业平均 49.8445.684.61105.51亿行业中值36.5938.052.4346.93亿1天益医疗-1742 ...

Core Viewpoint - The stock price of Kangtai Medical has plummeted significantly since its IPO, leading to a drastic reduction in market capitalization and shareholder value, prompting the major shareholder to initiate a share reduction plan [1][2][8]. Group 1: Stock Performance and Market Capitalization - Kangtai Medical's market capitalization has dropped from over 120 billion yuan to approximately 5.46 billion yuan, representing a decline of 95.58%, which equates to a loss of about 117 billion yuan [2][7]. - The stock price reached a peak of 307.03 yuan per share at the time of listing but has since fallen to a historical low of 13.97 yuan per share [2][7]. Group 2: Financial Performance - Since 2021, Kangtai Medical has experienced a continuous decline in net profit for four consecutive years, with a reported loss of 77.9 million yuan in 2024 [3][9]. - The company's revenue has also decreased, with 2021 revenue at 909 million yuan, down 35.15% year-on-year, and subsequent years showing further declines [10][11]. - Despite the financial downturn, the company has maintained high dividend payouts, totaling approximately 392 million yuan from 2020 to 2023, with the major shareholder receiving around 230 million yuan [4][12][13]. Group 3: Shareholder Actions - On May 8, 2024, the controlling shareholder, Hu Kun, announced plans to reduce his holdings by up to 12 million shares, which could yield approximately 168 million yuan [6][7]. - This marks Hu Kun's first instance of cashing out since the company's IPO, amidst a trend of frequent share reductions by executives and shareholders since 2021 [8]. Group 4: Product Quality and Legal Issues - In 2024, Kangtai Medical faced scrutiny over product quality, with several products failing to meet standards, resulting in a fine of 30,000 yuan [16][17]. - The company was also involved in a patent infringement lawsuit with Beijing Chao Si Electronic Technology, which was settled in December 2024 for 1 million USD [19][20][21].

中信建投证券股份有限公司关于康泰医学系统（秦皇岛） 股份有限公司 2024 年年度定期现场检查报告 | 保荐人名称：中信建投证券股份有限公司 被保荐公司简称：康泰医学 | | | --- | --- | | 保荐代表人姓名：孙泉 联系电话：021-68801584 | | | 保荐代表人姓名：刘乡镇 联系电话：021-68801584 | | | 现场检查人员姓名：孙泉 | | | 现场检查对应期间：2024 年 1 月 1 日至 2024 年 12 月 31 日 | | | 现场检查时间：2025 年 月 日 4 22 | | | 一、现场检查事项 现场检查意见 | | | 不 | | | （一）公司治理 否 适 | 是 | | 用 | | | 现场检查手段： | | | （1）查阅公司章程及各项规章制度；（2）查阅股东大会、董事会会议文件，包括会议通 | | | 知、签到表、会议记录、会议决议等；（3）实地查看公司主要生产经营场所，了解公司治 | | | 理及独立性情况；（4）查阅公司股东名册；（5）查阅公司信息披露文件。 | | | 1.公司章程和公司治理制度是否完备、合规 | √ | | 2.公司章程 ...

Summary of Key Points Core Viewpoint - 康泰医学's controlling shareholder, 胡坤, plans to reduce his stake in the company by up to 12 million shares, which is approximately 2.99% of the total share capital, through both centralized bidding and block trading methods [1] Group 1: Shareholder Reduction Plan - 胡坤 currently holds 188,189,252 shares, representing 46.84% of the total share capital [1] - The reduction will occur within three months starting from fifteen trading days after the announcement [1] - The reduction includes a maximum of 4 million shares through centralized bidding and 8 million shares through block trading [1] Group 2: Financial Performance - In 2024, 康泰医学 reported a revenue of 480 million yuan, a decrease of 35.76% compared to 2023 [4][5] - The net profit attributable to shareholders was -77.9 million yuan, a decline of 147% from the previous year [4][5] - The net cash flow from operating activities was 62.34 million yuan, down 65.56% year-on-year [4][5] Group 3: Fundraising Activities - 康泰医学 has raised a total of 1.117 billion yuan since its listing, including 4.17 billion yuan from its initial public offering [2][3] - The company issued 7 million convertible bonds in 2022, raising 700 million yuan, with a net amount of approximately 688 million yuan after expenses [3]

Group 1 - Shengxiang Bio plans to increase its investment in Hunan Shengwei Kunteng Biotechnology Co., Ltd. by 100 million yuan to enhance its industrial chain layout in the POCT field, resulting in a 44.6441% stake in Shengwei Kunteng after the investment [1] - Yaguang Technology's subsidiary Chengdu Yaguang signed a product pre-production agreement worth 101 million yuan, accounting for 10.56% of the company's audited revenue for the last fiscal year [1] Group 2 - Chutianlong's shareholder plans to reduce its stake by up to 3%, equating to 13.83 million shares, due to personal funding needs [2] - Naipu Mining intends to invest up to 45 million USD in Swiss Veritas Resources AG, acquiring a 22.5% stake to extend its industrial chain [2][3] Group 3 - Diri Medical's shareholder plans to reduce its stake by up to 3%, totaling 814.83 thousand shares, due to funding needs [4] - Kangtai Medical's controlling shareholder plans to reduce its stake by up to 2.99%, equating to 12 million shares [5] Group 4 - Iwu Bio's controlling shareholder plans to transfer up to 450 thousand shares through block trading, representing 0.86% of the total share capital [7] - Guokai Hengtai's four shareholders plan to collectively reduce their stake by up to 4.7%, totaling 22.94 million shares [9] Group 5 - *ST Zhongcheng submitted a hearing application to the Shenzhen Stock Exchange in response to a delisting notice [10] - Donghua Software's actual controller and associated parties plan to reduce their stake by up to 1%, totaling 32.05 million shares [12] Group 6 - Shandong Molong's shareholder reduced its H-share holdings by 107 million shares, representing 13.39% of the total share capital [12] - Yinbang Co.'s shareholder plans to reduce its stake by up to 1%, totaling 821.92 thousand shares [13] Group 7 - Jinxinnong reported April sales of 10.65 million pigs, generating sales revenue of 139 million yuan, with an average selling price of 15.05 yuan per kilogram [14] - Dongfang Jiasheng purchased 9.54 million shares of Zhonggu Logistics for approximately 99.72 million yuan, representing 4.18% of the company's net assets [15] Group 8 - Linglong Tire's controlling shareholder received a financing commitment of up to 270 million yuan for stock repurchase [16] - Wuchan Jinlun's shareholder plans to reduce its stake by up to 3%, totaling 619.77 thousand shares [18] Group 9 - Pengyao Environmental's directors and executives plan to collectively reduce their stake by up to 0.07% [19] - Ruihu Mould's controlling shareholder plans to reduce its stake by up to 1.92%, totaling 401.89 thousand shares [20] Group 10 - Electric Alloy's shareholder plans to reduce its stake by up to 0.63%, totaling 210.88 thousand shares [22] - Shanghai Xinyang's controlling shareholder plans to reduce its stake by up to 0.64%, totaling 200 thousand shares [24] Group 11 - Sujiao Ke's controlling shareholder plans to acquire up to 2% of the company's shares from a fund [26] - Heyuan Bio's shareholders plan to reduce their stake by up to 1%, totaling 649.04 thousand shares [27]

智通财经5月8日电，康泰医学(300869.SZ)公告称，公司控股股东、实际控制人胡坤计划在本公告披露 之日起十五个交易日后的三个月内，以集中竞价和大宗交易方式合计减持公司股份不超过1200万股，即 不超过公司总股本的2.9865%。减持原因是股东自身资金需求，减持股份来源为公司首次公开发行股票 并上市前取得的股份。 康泰医学：控股股东胡坤计划减持不超过总股本的2.99% ...

证券代码：300869 证券简称：康泰医学 公告编号：2025-037 债券代码：123151 债券简称：康医转债 康泰医学系统（秦皇岛）股份有限公司 关于控股股东、实际控制人减持股份预披露公告 公司控股股东、实际控制人胡坤先生保证向本公司提供的信息内容真实、准 确和完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证本公告内容与信息披露义务人提供的信息一 致。 特别提示： 公司控股股东、实际控制人胡坤先生持有康泰医学系统（秦皇岛）股份有限公 司（以下简称"公司""本公司"）股份 188,189,252 股（占公司总股本的 46.8362%）， 计划在本公告披露之日起十五个交易日后的三个月内以集中竞价和大宗交易方式 合计减持公司股份不超过 12,000,000 股（即不超过公司总股本的 2.9865%）。其 中，以集中竞价方式减持本公司股份不超过 4,000,000 股（即不超过公司总股本 的 0.9955%），以大宗交易方式减持本公司股份不超过 8,000,000 股（即不超过公 司总股本的 1.9910%）。 公司于近日收到控股股东、实际控制人胡坤先生出具的《关于减持计划的告知 函》，现 ...

Group 1: Company Performance - Wens Foodstuff's April chicken sales revenue was 2.543 billion yuan, a year-on-year decrease of 5.01% [1] - Wens Foodstuff sold 10.381 million chickens in April, a year-on-year increase of 10.87% [1] - Wens Foodstuff's average chicken selling price was 11.24 yuan/kg, a year-on-year decrease of 14.91% [1] - Zhongtong Bus's April vehicle sales volume was 1,046 units, a year-on-year decrease of 4.04% [1][2] - Kemin Food's April pig sales revenue reached 70.9048 million yuan, a year-on-year increase of 16.04% [3] - Muyuan Foods sold 6.573 million pigs in April, a year-on-year increase of 51.80% [5] - Muyuan Foods' pig sales revenue was 12.595 billion yuan in April, a year-on-year increase of 53.42% [5] - Xiamen Airport's April passenger throughput was 2.3881 million, a year-on-year increase of 7.73% [24] - Daqin Railway's April cargo transport volume was 30.62 million tons, a year-on-year increase of 0.99% [26] - Shaanxi Coal's April coal production was 14.24 million tons, a year-on-year decrease of 1.78% [28] Group 2: Industry Overview - Wens Foodstuff operates in the agriculture, forestry, animal husbandry, and fishery industry, specifically in pig farming [1] - Zhongtong Bus operates in the automotive industry, focusing on commercial vehicles [2] - Kemin Food operates in the food and beverage industry, specifically in food processing [3] - Muyuan Foods is also in the agriculture, forestry, animal husbandry, and fishery industry, focusing on pig farming [5] - Xiamen Airport is part of the transportation industry, specifically in airport operations [24] - Daqin Railway operates in the coal industry, focusing on coal mining and transportation [26] - Shaanxi Coal is also in the coal industry, focusing on coal mining and related services [28]